

Luxembourg, 27/02/2023

Environmental and Social Data Sheet

Overview

Project Name: SOM BIOTECH (IEU TI)

Project Number: 20220519
Country: Spain

Project Description: The project supports the research and development activities of the

promoter, in particular its focus on repurposing existing drugs to target orphan diseases and therapeutic areas of unmet medical needs.

EIA required: No

Invest EU sustainability proofing required Yes

Project included in Carbon Footprint Exercise¹: No

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project neither falls under Annex I nor Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU, therefore the project is not subject to an EIA

Climate Assessment

Research and development investment activities, such as those present in this project, neither present significant negative nor positive impacts for climate aspects.

The project has been assessed for Paris alignment and is considered to be aligned with the Paris Agreement, as defined in the EIB Climate Bank Roadmap.

EIB Paris Alignment for Counterparties (PATH) Framework

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Social Assessment

The Project does not have any significant negative social impacts, as the Promoter is expected to carry out its activities in compliance with applicable local labour and social standards.

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.



Luxembourg, 27/02/2023

For preclinical and clinical trials, the Promoter retain the services of subcontractors (such as Clinical Research Organisations) and relies on their official policies, processes and qualifications, considering the higher level of scrutiny and responsibility involved in such operations.

Other Environmental and Social Aspects

Considering the Promoter's small size and early-stage focus, currently it does not have a quality certification. However, it is working towards a normalised and documented internal control system and internal map of policies, procedures and Standard Operating Procedures (SOPs) in sights of implementing a quality certification in the near future.

If successful, the project is expected to lead to important social benefits, considering the targeted indications and the level of unmet medical need.

Through the R&D activities and investments, the Promoter is also expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The project's activities are not covered by the EU Directive 2011/92/EU amended by Directive 2014/52/EU. The research activities will be executed in existing and already authorised research facilities, expected to be in compliance with all applicable EU environmental legislation.

The project is not expected to result in any significant additional negative environmental or social impacts.

Sustainability proofing conclusion: The Project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environmental, climate and social information and based on the review of the likely significant environmental, climate and social risks and impacts and the mitigation measures and management systems in place, the Project is deemed to have low residual environmental, climate and social risks and impacts. No further sustainability proofing is therefore required.

Considering the above, the project is considered acceptable for Bank financing in environmental and social terms.